Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481078 · ClinicalTrials.gov registry record · Phase 2
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT00481078: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00481078 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 94 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481078, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with stage III or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving carboplatin and paclitaxel together with vorinostat is more effective than giving carboplatin and paclitaxel together with a placebo in treating non-small cell lung cancer
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG carboplatin
- DRUG vorinostat
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481078
The ClinicalTrials.gov registry entry for NCT00481078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00481078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00481078 about?
NCT00481078 is a clinical study titled "Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer". This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with stage III or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel...
What is the current status of trial NCT00481078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2007-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00481078?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), carboplatin (DRUG), vorinostat (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00481078?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.